These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 19099730

  • 1. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT, Jiang SY, Li BS, Yang LL.
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [Abstract] [Full Text] [Related]

  • 2. Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.
    Gabor KM, Schermann G, Lautner-Csorba O, Rarosi F, Erdelyi DJ, Endreffy E, Berek K, Bartyik K, Bereczki C, Szalai C, Semsei AF.
    Pediatr Blood Cancer; 2015 Apr; 62(4):622-8. PubMed ID: 25557962
    [Abstract] [Full Text] [Related]

  • 3. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
    Falk IJ, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K.
    Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
    [Abstract] [Full Text] [Related]

  • 4. Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.
    Banklau C, Jindadamrongwech S, Sawangpanich R, Apibal S, Hongeng S, Paisooksantivatana K, Pakakasama S.
    Hematol Oncol Stem Cell Ther; 2010 Dec; 3(3):103-8. PubMed ID: 20890066
    [Abstract] [Full Text] [Related]

  • 5. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK, Mohanan E, Janet NB, Srivastava VM, Shaji RV, Zhang W, Abraham A, Viswabandya A, George B, Chandy M, Srivastava A, Mathews V, Balasubramanian P.
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [Abstract] [Full Text] [Related]

  • 6. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.
    Xu PP, Chen BA, Feng JF, Cheng L, Xia GH, Li YF, Qian J, Ding JH, Lu ZH, Wang XM, Xu K, Schultz M.
    Chin Med J (Engl); 2012 Jun; 125(12):2137-43. PubMed ID: 22884143
    [Abstract] [Full Text] [Related]

  • 7. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [Abstract] [Full Text] [Related]

  • 8. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
    Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R.
    Blood; 2003 Feb 15; 101(4):1270-6. PubMed ID: 12406912
    [Abstract] [Full Text] [Related]

  • 9. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.
    Biochem Pharmacol; 2009 Jun 15; 77(12):1780-6. PubMed ID: 19428333
    [Abstract] [Full Text] [Related]

  • 10. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M, Hohenlöchter B, Schulze-Westhoff P, Zimmermann M, Ritter J, Jürgens H, Boos J.
    Klin Padiatr; 1996 Jun 15; 208(4):151-9. PubMed ID: 8926681
    [Abstract] [Full Text] [Related]

  • 11. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
    Huang M, Inukai T, Miyake K, Tanaka Y, Kagami K, Abe M, Goto H, Minegishi M, Iwamoto S, Sugihara E, Watanabe A, Somazu S, Shinohara T, Oshiro H, Akahane K, Goi K, Sugita K.
    Cancer Med; 2018 Apr 15; 7(4):1297-1316. PubMed ID: 29473342
    [Abstract] [Full Text] [Related]

  • 12. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
    Abraham A, Varatharajan S, Abbas S, Zhang W, Shaji RV, Ahmed R, Abraham A, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P.
    Pharmacogenomics; 2012 Feb 15; 13(3):269-82. PubMed ID: 22304580
    [Abstract] [Full Text] [Related]

  • 13. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
    Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R.
    J Pharmacol Exp Ther; 2007 Dec 15; 323(3):935-45. PubMed ID: 17855478
    [Abstract] [Full Text] [Related]

  • 14. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside.
    Flasshove M, Strumberg D, Ayscue L, Mitchell BS, Tirier C, Heit W, Seeber S, Schütte J.
    Leukemia; 1994 May 15; 8(5):780-5. PubMed ID: 7514246
    [Abstract] [Full Text] [Related]

  • 15. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec 15; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 16. Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells.
    Ohta T, Hori H, Ogawa M, Miyahara M, Kawasaki H, Taniguchi N, Komada Y.
    Oncol Rep; 2004 Nov 15; 12(5):1115-20. PubMed ID: 15492802
    [Abstract] [Full Text] [Related]

  • 17. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
    Song JH, Kim SH, Kweon SH, Lee TH, Kim HJ, Kim HJ, Kim TS.
    Int J Oncol; 2009 Apr 15; 34(4):1165-71. PubMed ID: 19287976
    [Abstract] [Full Text] [Related]

  • 18. Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity.
    Hubeek I, Peters GJ, Broekhuizen AJ, Talianidis I, Schouten van Meeteren AY, van Wering ER, Gibson B, Creutzig U, Kaspers GJ.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct 15; 23(8-9):1351-6. PubMed ID: 15571257
    [Abstract] [Full Text] [Related]

  • 19. Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.
    Jaramillo AC, Bergman AM, Comijn EM, Jansen G, Kaspers GJL, Cloos J, Peters GJ.
    Nucleosides Nucleotides Nucleic Acids; 2020 Oct 15; 39(10-12):1346. PubMed ID: 32727269
    [Abstract] [Full Text] [Related]

  • 20. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
    Candelaria M, Corrales-Alfaro C, Gutiérrez-Hernández O, Díaz-Chavez J, Labardini-Méndez J, Vidal-Millán S, Herrera LA.
    Chemotherapy; 2016 Oct 15; 61(6):313-8. PubMed ID: 27119162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.